Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 Next >
Ocugen Provides Business Update with First Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at May 2024 Investor Conferences
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at Investing in Cures Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Clinical Showcase Webcast Now Available
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at 2024 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at Pharma Market Research Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback